Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Want to cut your energy bills? Here’s how five experts are doing it 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
ATLANTA, April 06, 2016 -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota’s CEO & President Joseph Patti, PhD will present a corporate overview and update at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 10:00 a.m. ET in New York.
A live webcast of the presentation can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.biotapharma.com or at http://wsw.com/webcast/needham76/bota.
A replay of the webcast will be archived for 30 days following the presentation.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics currently being evaluated in the Company’s ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals, Inc.
Contact: Mark Colonnese Executive Vice President and Chief Financial Officer (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
